IN2014DN09939A - - Google Patents
Info
- Publication number
- IN2014DN09939A IN2014DN09939A IN9939DEN2014A IN2014DN09939A IN 2014DN09939 A IN2014DN09939 A IN 2014DN09939A IN 9939DEN2014 A IN9939DEN2014 A IN 9939DEN2014A IN 2014DN09939 A IN2014DN09939 A IN 2014DN09939A
- Authority
- IN
- India
- Prior art keywords
- ethyl
- imidazo
- pyridin
- carbonyl
- phenyl
- Prior art date
Links
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 229910002483 Cu Ka Inorganic materials 0.000 abstract 1
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
Abstract
A process for the preparation of essentially pure, crystalline, N-[({2-[4-(2-Ethyl-4,6- dimethyHH-imidazo[4,5-c]pyridin-l-yl)phenyl]ethyl}amino)carbonyl]-4- methylbenzenesulfonamide Polymorph Form A, which has a powder X-ray diffraction pattern obtained by irradiation with Cu Ka radiation which includes main peaks at 2- Theta° 9.8,13.2,13.4, 13.7, 14.1, 17.5, 19.0, 21.6, 24.0 and 25.7+/-0.2, characterized by crystallization from a solution of A^-[({2-[4-(2-Ethyl-4,6-dimethyl-li^-imidazo[4,5- c]pyridin-l-yl)phenyl]ethyl}amino)carbonyl]~4-methylbenzenesulfonamide in ethyl acetate or acetone.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66059205P | 2005-03-11 | 2005-03-11 | |
| PCT/IB2006/000754 WO2006095268A1 (en) | 2005-03-11 | 2006-03-01 | Crystal forms of an imidazole derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09939A true IN2014DN09939A (en) | 2015-08-14 |
Family
ID=36649530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9939DEN2014 IN2014DN09939A (en) | 2005-03-11 | 2006-03-01 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7960407B2 (en) |
| EP (1) | EP1861400B1 (en) |
| JP (1) | JP5069415B2 (en) |
| KR (1) | KR100911073B1 (en) |
| CN (1) | CN101137656B (en) |
| AR (1) | AR055567A1 (en) |
| AT (1) | ATE469150T1 (en) |
| AU (1) | AU2006221699A1 (en) |
| BR (1) | BRPI0608819B8 (en) |
| CA (1) | CA2600510C (en) |
| DE (1) | DE602006014516D1 (en) |
| ES (1) | ES2344310T3 (en) |
| IL (1) | IL185145A0 (en) |
| IN (1) | IN2014DN09939A (en) |
| MX (1) | MX2007011110A (en) |
| NL (1) | NL300944I2 (en) |
| PL (1) | PL1861400T3 (en) |
| RU (1) | RU2357968C1 (en) |
| TW (1) | TW200643021A (en) |
| WO (1) | WO2006095268A1 (en) |
| ZA (1) | ZA200707568B (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009295308A1 (en) * | 2008-09-25 | 2010-04-01 | Merck Canada Inc. | Beta-carboline sulphonylurea derivatives as EP4 receptor antagonists |
| ES2960438T3 (en) | 2009-04-22 | 2024-03-04 | Askat Inc | Selective EP4 receptor antagonist substance for cancer treatment |
| BR112012020236A2 (en) * | 2010-02-22 | 2016-05-17 | Raqualia Pharma Inc | use of a compound with ep4 antagonistic activity or a pharmaceutically acceptable salt thereof, use of a compound of formula (i), (ii), (iii), (iv), (va) or (vb), or a salt pharmaceutically acceptable drug thereof, pharmaceutical composition and method for treating il-23 mediated diseases in an animal subject, including a mammalian subject |
| RU2451680C1 (en) | 2011-02-21 | 2012-05-27 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | Clatrate complex of cyclodextrine or arabinogalactane with 9-phenyl-symm-octahydroselenoxantene, its production method (versions), pharmaceutical composition and medication |
| RU2464042C1 (en) * | 2011-03-31 | 2012-10-20 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | β-CYCLODEXTRINE CLATHRATE COMPLEX WITH 5-HYDROXY-4-AMINOMETHYL-1 -CYCLOHEXYL(OR CYCLOHEPTYL)-3-ALKOXYCARBONYLINDOLE DERIVATIVE, METHOD FOR PREPARING IT (VERSIONS), PHARMACEUTICAL COMPOSITION AND DRUG |
| US20160317514A1 (en) * | 2013-03-19 | 2016-11-03 | Askat Inc. | Use of ep4 receptor antagonists in the treatment of cartilage disease |
| US10391086B2 (en) | 2013-03-19 | 2019-08-27 | Askat Inc. | Use of EP4 receptor antagonists in the treatment of cartilage disease |
| PT3113774T (en) | 2014-03-06 | 2022-02-28 | Elanco Animal Health Incorporated | Compositions of grapiprant and methods for using the same |
| US12109218B2 (en) | 2014-12-09 | 2024-10-08 | Aratana Therapeutics, Inc. | Compositions of grapiprant and methods for using the same |
| JP6535683B2 (en) * | 2014-03-06 | 2019-06-26 | アラタナ セラピューティクス、 インコーポレイテッド | Graphiplant crystal form |
| US10342785B2 (en) | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
| JP2021522211A (en) | 2018-04-16 | 2021-08-30 | アリーズ セラピューティクス， インコーポレイテッド | EP4 inhibitor and its use |
| WO2019245590A1 (en) | 2018-06-18 | 2019-12-26 | Avista Pharma Solutions, Inc. | Chemical compounds |
| JP2021530487A (en) * | 2018-07-11 | 2021-11-11 | アリーズ セラピューティクス， インコーポレイテッド | EP4 inhibitor and its synthesis |
| WO2020014465A1 (en) | 2018-07-11 | 2020-01-16 | Arrys Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| EP3917932A4 (en) | 2019-01-30 | 2022-09-28 | Avista Pharma Solutions, Inc. | Chemical compounds |
| CA3128346A1 (en) | 2019-01-30 | 2020-08-06 | Avista Pharma Solutions, Inc. | Synthetic process and novel intermediates |
| US11254675B2 (en) | 2019-08-12 | 2022-02-22 | Cadila Healthcare Limited | Process for preparation of grapiprant |
| WO2021226162A1 (en) | 2020-05-05 | 2021-11-11 | Arrys Therapeutics, Inc. | Ep4 antagonists and their use in the treatment of proliferative diseases |
| CA3223173A1 (en) * | 2021-07-30 | 2023-02-02 | Raqualia Pharma Inc. | Crystalline forms |
| CN116478155B (en) * | 2022-01-17 | 2025-06-13 | 洛阳惠中兽药有限公司 | A preparation method of glapiron and its intermediates |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL110296A (en) * | 1993-07-16 | 1999-12-31 | Smithkline Beecham Corp | Imidazole compounds process for their preparation and pharmaceutical compositions containing them |
| HN2001000224A (en) * | 2000-10-19 | 2002-06-13 | Pfizer | IMIDAZOL COMPOUNDS CONDENSED WITH ARILO OR HETEROARILO AS ANTI - INFLAMMATORY AND ANALGESIC AGENTS. |
| PL373246A1 (en) * | 2002-04-12 | 2005-08-22 | Pfizer Inc. | Use of ep4 receptor ligands in the treatment of il-6 involved diseases |
-
2006
- 2006-03-01 DE DE602006014516T patent/DE602006014516D1/de active Active
- 2006-03-01 US US11/908,163 patent/US7960407B2/en active Active
- 2006-03-01 PL PL06710609T patent/PL1861400T3/en unknown
- 2006-03-01 CN CN2006800079642A patent/CN101137656B/en active Active
- 2006-03-01 EP EP06710609A patent/EP1861400B1/en active Active
- 2006-03-01 BR BRPI0608819A patent/BRPI0608819B8/en active IP Right Grant
- 2006-03-01 ES ES06710609T patent/ES2344310T3/en active Active
- 2006-03-01 AU AU2006221699A patent/AU2006221699A1/en not_active Abandoned
- 2006-03-01 AT AT06710609T patent/ATE469150T1/en not_active IP Right Cessation
- 2006-03-01 RU RU2007133802/04A patent/RU2357968C1/en active
- 2006-03-01 KR KR1020077020701A patent/KR100911073B1/en active Active
- 2006-03-01 CA CA2600510A patent/CA2600510C/en active Active
- 2006-03-01 WO PCT/IB2006/000754 patent/WO2006095268A1/en not_active Ceased
- 2006-03-01 IN IN9939DEN2014 patent/IN2014DN09939A/en unknown
- 2006-03-01 MX MX2007011110A patent/MX2007011110A/en active IP Right Grant
- 2006-03-09 TW TW095108018A patent/TW200643021A/en unknown
- 2006-03-09 AR ARP060100886A patent/AR055567A1/en unknown
- 2006-03-10 JP JP2006065731A patent/JP5069415B2/en active Active
-
2007
- 2007-08-09 IL IL185145A patent/IL185145A0/en unknown
- 2007-09-03 ZA ZA200707568A patent/ZA200707568B/en unknown
-
2018
- 2018-07-05 NL NL300944C patent/NL300944I2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NL300944I2 (en) | 2018-08-07 |
| KR20070103484A (en) | 2007-10-23 |
| AR055567A1 (en) | 2007-08-22 |
| BRPI0608819A8 (en) | 2017-10-10 |
| US7960407B2 (en) | 2011-06-14 |
| TW200643021A (en) | 2006-12-16 |
| RU2357968C1 (en) | 2009-06-10 |
| JP2006249089A (en) | 2006-09-21 |
| EP1861400A1 (en) | 2007-12-05 |
| CN101137656B (en) | 2010-12-22 |
| WO2006095268A1 (en) | 2006-09-14 |
| MX2007011110A (en) | 2008-02-21 |
| IL185145A0 (en) | 2007-12-03 |
| US20090018158A1 (en) | 2009-01-15 |
| CN101137656A (en) | 2008-03-05 |
| CA2600510A1 (en) | 2006-09-14 |
| ES2344310T3 (en) | 2010-08-24 |
| KR100911073B1 (en) | 2009-08-06 |
| AU2006221699A1 (en) | 2006-09-14 |
| PL1861400T3 (en) | 2010-09-30 |
| ZA200707568B (en) | 2009-09-30 |
| EP1861400B1 (en) | 2010-05-26 |
| CA2600510C (en) | 2010-11-02 |
| JP5069415B2 (en) | 2012-11-07 |
| RU2007133802A (en) | 2009-03-20 |
| BRPI0608819B8 (en) | 2021-05-25 |
| BRPI0608819B1 (en) | 2019-11-12 |
| DE602006014516D1 (en) | 2010-07-08 |
| ATE469150T1 (en) | 2010-06-15 |
| BRPI0608819A2 (en) | 2010-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN09939A (en) | ||
| UA97478C2 (en) | Crystalline form vi of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| UA83720C2 (en) | New cyrstalline form v of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| UA83718C2 (en) | New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| UA97351C2 (en) | Coumarin derivative having antitumor activity | |
| JO2548B1 (en) | Beta Crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | |
| JO3360B1 (en) | New Crystalline From III of Agomelatine, A process for It's preparation and Pharmaceutical compositions Containing it. | |
| NO20091858L (en) | Hydrobenzamide derivatives as inhibitors of HSP90 | |
| MX2010004232A (en) | Pyrimidyl indoline compound. | |
| NO20064596L (en) | Delta crystalline form of ivabradine hydrochloride, process for its preparation and pharmaceutical compositions containing the | |
| MY143557A (en) | Beta-crystalline form of perindopril arginine salt, process for its preparation, and pharmaceutical compositions containing it | |
| UA89905C2 (en) | α-CRYSTALLINE FORM OF PERINDOPRIL ARGININE SALT, METHOD FOR MAKING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | |
| MY147951A (en) | Crystalline potassium salt of lipoxin a? analogs | |
| TN2012000619A1 (en) | CRYSTALLINE DELTA FORM OF PERINOPRIL ARGININE SALT, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
| WO2008090962A1 (en) | Composition for external application to skin | |
| MY142738A (en) | Preparation method of a novel beta crystalline form of perindopril tert-butylamine salt | |
| TNSN05076A1 (en) | New alpha crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it | |
| TNSN05077A1 (en) | New y crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it | |
| MY138209A (en) | New (y) crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it. | |
| MA28192A1 (en) | NOVEL β-CRYSTALLINE FORM OF TERT-BUTYLAMINE SALT OF PERINDOPRILL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. | |
| GEP20094652B (en) | New cyrstalline form v of agomelatine, a process for its preparation and pharmaceutical compositions containing it | |
| MA28191A1 (en) | NOVEL CRYSTALLINE FORM "ALPHA" OF TERT-BUTYLAMINE SALT OF PERINDOPRILL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
| TH88290B (en) | A new type III crystalline type of agomelatine, its preparation process and pharmaceutical constituents containing this substance. |